![Brain Scientists Are Tripping Out Over Psychedelics - podcast episode cover](https://media.npr.org/assets/img/2022/12/20/gettyimages-145912413_sq-0fd4c42408daf73ff5139abd6d9879c8be0fac1f.jpg?s=3000&c=66&f=jpg)
Episode description
Psychedelic drugs – like LSD, salvia, ayahuasca, Ibogaine, MDMA (AKA ecstasy), or psilocybin (AKA 'magic mushrooms' or 'shrooms') – are experiencing a resurgence of interest in their potential medical benefits.At the Neuroscience 2022 meeting held by the Society of Neuroscience, the appetite for psychedelic research permeated the sessions, discussions, and even after-hours barroom talk — drawing in researchers, neuroscientists, companies, reporters, and advocates alike.
"In the last couple of years there has been a lot of excitement in psychedelics. I think it started first in the popular media." says Alex Kwan, associate professor at Cornell University. "Neuroscience, actually, I think took another year or two to catch on."
Today on the show, host Aaron Scott and NPR's brain correspondent Jon Hamilton chat psychedelic drugs — whether this renewed interest will represent incremental or revolutionary changes in the fields of medicine, psychology, and neuroscience.
Learn more about sponsor message choices: podcastchoices.com/adchoices
NPR Privacy Policy